La chaîne d'options affiche les données clés des options sur actions de Danaher à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour Danaher..

Danaher (NYSE:DHR) Stock, Chaîne d'Options

Danaher

In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in the life science and diagnostic industries after the late 2023 divesititure of its environmental and applied solutions group, Veralto.

Danaher Corp

DEUTSCHE EUROSHOP UNS/ADR by Deutsche Euroshop AG

Deutsche EuroShop AG

On Tuesday,&nbsp;Danaher Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) reported third-quarter sales of $5.79 billion, up 3% year-over-year, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/news/earnings/24/10/41449367/life-science-giant-danaher-q3-earnings-revenue-and-eps-beat-sticks-to-annual-guidance" rel="noreferrer noopener">consensus of $5.59 billion</a>.&nbsp;
Guidance: Danaher reaffirms that in fiscal year 2024, non-GAAP core revenue will be down in the low single digits year over year.
The company forecasts that 2024 bioprocessing core revenue will decline in the low single digits, and Cepheid 2024 respiratory revenues will be around&nbsp;$1.7 billion compared to prior guidance of $1.6 billion.
William Blair reports that Danaher&#8217;s third-quarter earnings aligned with expectations, particularly regarding the ongoing recovery in bioprocessing, though capital expenditures remain weak.
The analyst highlights that the recovery theme is progressing as anticipated, with results reflecting similar trends seen in industry conference updates earlier in the quarter.
Third-quarter book-to-bill improved to approximately 1.0x, up from 0.80x a year ago, and a high-single-digit increase in sequential orders further supported the bioprocessing rebound.
In the equipment segment, life sciences instruments saw a mid-single-digit decline, in line with forecasts and intra-quarter observations.
Meanwhile, diagnostics performed well, and Cepheid&#8217;s respiratory revenue again exceeded expectations.
On guidance, management expects mid- to high-single-digit core growth in the fourth quarter in Biotechnology. The analyst expects the focus of the call will be on the fourth-quarter exit rate for bioprocessing, any initial insights into 2025, capital equipment weakness, and updated thoughts on China.
William Blair keeps the Outperform rating. Goldman Sachs maintains a Neutral rating,<a href="https://www.benzinga.com/quote/dhr/analyst-ratings"> with a price target of $250.</a>
Price Action: DHR stock is down 4.01% at $261.18 at last check Tuesday.
Photo via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41462205/with-fda-approval-irhythm-may-be-able-to-lift-regulatory-overhang-investor-skeptici" target="_blank" rel="noreferrer noopener">With FDA Approval iRhythm May Be Able To Lift Regulatory Overhang, Investor Skepticism, Analyst Says</a>.</li>
</ul>

Analyst Color

Earnings

Equities

News

Guidance

Health Care

Price Target

Reiteration

Analyst Ratings

Trading Ideas

General

Danaher's Q3 Earnings Boosted By Bioprocessing Order Growth, Analyst Maintain Stock Rating

Wall Street traded lower for the second consecutive day on Tuesday, as investor sentiment turned cautious with the U.S. presidential election <a href="https://www.benzinga.com/topic/2024-elections">just two weeks away. </a>
Concerns over U.S. fiscal policies and potential shifts in economic direction fueled the pause in risk-taking.
The International Monetary Fund (IMF) upgraded its U.S. growth forecasts for 2024 and 2025 in the latest World Economic Outlook, while also flagging rising concerns about the country's debt trajectory, warning that with current large fiscal deficits, &#8220;the U.S. public debt is not stabilized.&#8221;
Commodities were the standout performers on Tuesday, with both metals and energy experiencing notable gains.
Gold, tracked by the SPDR Gold Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLD#NYSE">GLD</a>), rose 0.8%, pushing further into record territory. This increase extended its year-to-date performance to 34%, positioning gold for its strongest <a href="https://www.benzinga.com/markets/bonds/24/10/41455678/gold-on-track-for-best-year-since-1979-veteran-investor-says-sell-bonds-buy-gold">annual gain since 1979.</a> Gold miners, as represented by the VanEck Gold Miners ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GDX#NYSE">GDX</a>), rallied for the ninth consecutive session, hitting their highest levels in over four years.
Silver, tracked by the iShares Silver Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLV#NYSE">SLV</a>), surged 2.8%, reaching levels not seen since October 2012.
Oil prices rallied nearly 3%, building on a 2% surge from Monday. U.S. Treasury yields ticked up modestly on Tuesday following Monday's spike, with the 10-year yield settling at 4.21%.
Meanwhile, the U.S. Dollar Index (DXY), tracked by the Invesco DB USD Index Bullish Fund ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UUP#NYSE">UUP</a>), climbed past the 104 mark, continuing its steady ascent and eyeing a fourth consecutive week of gains.
In the cryptocurrency market, Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) fell 0.5%, dipping to around $67,000 and marking its second consecutive day of declines.
<h3 class="wp-block-heading">Tuesday&#8217;s Performance In US Major Indices, ETFs</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1-day %change</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>42,907.57</td>
<td>-0.1 %</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,840.39</td>
<td>-0.2%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>20,291.15</td>
<td>-0.3%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,228.60</td>
<td>-0.5%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 12:35 p.m. ET</figcaption></figure>
According to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent102224&amp;t=be2bearmibe3na1">Benzinga Pro</a> data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) fell 0.3% to $581.79.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>)&nbsp;inched 0.1% lower to $429.14.</li>
<li>The tech-heavy Invesco QQQ Trust Series (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) fell 0.4% to $493.29.</li>
<li>The iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) fell 0.5% $221.04.</li>
<li>The Energy Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>) outperformed, up 0.6%. The Industrial Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLI#NYSE">XLI</a>) lagged, down 1.1%.</li>
</ul>
<h3 class="wp-block-heading">Tuesday&#8217;s Stock Performers</h3>
General Motors Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>) surged 9%, on track for its strongest session in nearly a year, after reporting stronger-than-expected earnings and announcing an additional $5 billion share buyback program extending into next year.
Other stocks reacting to earnings include: 
<ul>
<li>Southern Copper Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCCO#NYSE">SCCO</a>), up 1.5%</li>
<li>Nucor Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUE#NYSE">NUE</a>), down 6%</li>
<li>W.R. Berkley Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WRB#NYSE">WRB</a>), down 4.6%</li>
<li>Zion Bancorp. N.A. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZION#NASDAQ">ZION</a>), up 6.8%</li>
<li>Wintrust Financial Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WTFC#NASDAQ">WTFC</a>), up 1.6%</li>
<li>Philip Morris International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PM#NYSE">PM</a>), up 8.8%</li>
<li>GE Aerospace (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GE#NYSE">GE</a>), down over 8%</li>
<li>Danaher Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>), down 3%</li>
<li>Verizon Communications Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VZ#NYSE">VZ</a>), down 4.4%</li>
<li>RTX Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RTX#NYSE">RTX</a>), down 0.4%</li>
<li>Lockheed Martin Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMT#NYSE">LMT</a>), down 5.8%</li>
<li>Fiserv Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FI#NYSE">FI</a>), down 0.4%</li>
<li>Moodys Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCO#NYSE">MCO</a>) down 4.5%</li>
<li>3M Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMM#NYSE">MMM</a>), down 0.9%</li>
<li>Freeport-McMoran Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FCX#NYSE">FCX</a>), up 1.4%</li>
<li>Kimberly-Clark Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMB#NYSE">KMB</a>), down 4%</li>
<li>PulteGroup Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHM#NYSE">PHM</a>), down 5.7%</li>
</ul>
Large-cap companies reporting earnings after the close include Texas Instruments Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXN#NASDAQ">TXN</a>), Baker Hughes Co. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKR#NASDAQ">BKR</a>), Seagate Technology Holdings PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STX#NASDAQ">STX</a>), Packaging Corporation of America (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PKG#NYSE">PKG</a>), Manhattan Associates Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MANH#NASDAQ">MANH</a>), East West Bancorp. Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EWBC#NASDAQ">EWBC</a>) and Enphase Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENPH#NASDAQ">ENPH</a>)
Now Read:
<ul>
<li><a href="https://www.benzinga.com/government/24/10/41455013/how-us-elections-could-impact-us-dollar-goldman-sachs-expects-greenback-will-remain-stronger-for-lon">How US Elections Could Impact US Dollar: Goldman Sachs Expects Greenback Will Remain &#8216;Stronger For Longer&#8217;</a></li>
</ul>
Image: Shutterstock

Large Cap

Mid Cap

Sector ETFs

Broad U.S. Equity ETFs

New ETFs

Commodities

Currency ETFs

Small Cap

Tech

ETFs

$BTC

SPDR Dow Jones Industrial Average ETF Trust

ENPH

EWBC

Market Vectors ETF Trust Market Vectors Gold Miners

MANH

SCCO

PowerShares DB US Dollar Index Bullish Fund

WTFC

ZION

Stocks Fall, GM Eyes Best Day In A Year, Gold Breaks Records, Silver Hits 12-Year Highs: What's Driving Markets Tuesday?

Deep-pocketed investors have adopted a bearish approach towards Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in DHR usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 18 extraordinary options activities for Danaher. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 33% leaning bullish and 44% bearish. Among these notable options, 13 are puts, totaling $1,262,580, and 5 are calls, amounting to $222,084.
<h3>What's The Price Target?</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $150.0 to $290.0 for Danaher over the last 3 months. 
<h3>Volume &amp; Open Interest Trends</h3>
In today's trading context, the average open interest for options of Danaher stands at 425.44, with a total volume reaching 2,026.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Danaher, situated within the strike price corridor from $150.0 to $290.0, throughout the last 30 days.
<h3>Danaher Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1729611930_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>DHR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$25.4</td>
<td>$24.8</td>
<td>$25.4</td>
<td>$290.00</td>
<td>$151.8K</td>
<td>245</td>
<td style="text-align: right;">60</td>
</tr>
<tr>
<td>DHR</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$27.4</td>
<td>$24.3</td>
<td>$25.55</td>
<td>$290.00</td>
<td>$145.6K</td>
<td>245</td>
<td style="text-align: right;">117</td>
</tr>
<tr>
<td>DHR</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>12/20/24</td>
<td>$19.3</td>
<td>$16.3</td>
<td>$17.75</td>
<td>$280.00</td>
<td>$106.5K</td>
<td>1.1K</td>
<td style="text-align: right;">275</td>
</tr>
<tr>
<td>DHR</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$19.3</td>
<td>$16.4</td>
<td>$18.43</td>
<td>$280.00</td>
<td>$105.0K</td>
<td>1.1K</td>
<td style="text-align: right;">332</td>
</tr>
<tr>
<td>DHR</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$16.1</td>
<td>$15.6</td>
<td>$16.1</td>
<td>$280.00</td>
<td>$103.0K</td>
<td>1.1K</td>
<td style="text-align: right;">396</td>
</tr>
</tbody>
</table>

<h3>About Danaher</h3>
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in the life science and diagnostic industries after the late 2023 divesititure of its environmental and applied solutions group, Veralto.
Having examined the options trading patterns of Danaher, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Current Position of Danaher</h3>
<ul>
<li>With a volume of 1,530,674, the price of DHR is down -2.38% at $265.61. </li>
<li>RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.</li>
<li>Next earnings are expected to be released in 0 days.</li>
</ul>
<h3>Professional Analyst Ratings for Danaher</h3>
A total of 2 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $296.5.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Evercore ISI Group continues to hold a Outperform rating for Danaher, targeting a price of $278. 
&#x2A; In a cautious move, an analyst from Stephens &amp; Co. downgraded its rating to Overweight, setting a price target of $315. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Danaher options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

Markets

A Closer Look at Danaher's Options Market Dynamics

On Tuesday,&nbsp;Danaher Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) reported third-quarter sales of $5.79 billion, up 3% year-over-year, beating the <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $5.59 billion</a>.&nbsp;
Non-GAAP core revenue increased by 0.5%, compared to the expectations of a decline in <a target="_blank" href="https://www.benzinga.com/news/earnings/24/07/39907956/life-science-giant-danahers-q2-earnings-beat-estimates-on-sustained-positive-momentum-in-bioprocess" rel="noreferrer noopener">the low-single digits</a>.
Danaher reported second-quarter adjusted EPS of $1.71, <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/n41445769/danaher-reports-third-quarter-2024-results" rel="noreferrer noopener">beating the consensus of $1.57</a>.
Operating cash flow was $1.5 billion, and non-GAAP&nbsp;free cash flow was $1.2 billion.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41122971/danaher-is-poised-for-a-good-year-in-bioprocessing-analyst" rel="noreferrer noopener">Danaher Is Poised For &#8216;A Good Year In Bioprocessing&#8217;: Analyst</a>.
Rainer Blair, President and CEO, stated, &#8220;Our team delivered strong third-quarter results, including better-than-expected revenue growth. We were especially pleased with the continued positive momentum in our bioprocessing business and believe Cepheid gained market share in molecular testing again this quarter.&#8221;
Biotechnology&nbsp;<a target="_blank" href="https://filecache.investorroom.com/mr5ir_danaher/896/Q3%202024%20Danaher%20Earnings%20Presentation.pdf" rel="noreferrer noopener">sales</a> remained almost constant at $1.65 billion compared to $1.66 billion a year ago.
Life Sciences segment sales increased slightly from $1.71 billion to $1.78 billion. Diagnostic sales increased from $2.25 billion to $2.36 billion.
The operating margin of 27.5% came in above the guidance of around 26%.
Guidance: Danaher&nbsp;<a target="_blank" href="https://filecache.investorroom.com/mr5ir_danaher/894/Q3%202024%20Earnings%20Supplement.pdf" rel="noreferrer noopener">reaffirms</a> that in fiscal year 2024, non-GAAP core revenue will be down in the low single digits year over year.
The company forecasts that 2024 bioprocessing core revenue will decline in the low single digits, and Cepheid 2024 respiratory revenues will be around&nbsp;$1.7 billion compared to prior guidance of $1.6 billion.
For 2024, Danaher forecasts an adjusted operating profit margin of around 29%.
For the fourth quarter of 2024, Danaher anticipates adjusted core revenue to decline in the low-single digits year over year.
Bioprocessing core revenue growth is expected to be in the high single digits, which assumes gradual improvement continues. Cepheid respiratory revenue is expected to be approximately $350 million, with an adjusted operating profit margin of around 30%.
Price Action: At last check on Tuesday, DHR stock was trading 2.18% higher at $278 during the premarket session.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41437696/newly-listed-guardian-pharmacy-is-well-positioned-in-highly-fragmented-market-analy" target="_blank" rel="noreferrer noopener">Newly Listed Guardian Pharmacy Is Well Positioned In Highly Fragmented Market, Analyst Initiates With Buy Rating</a>.</li>
</ul>

Movers

Life Science Giant Danaher Q3 Earnings: Revenue And EPS Beat, Sticks To  Annual Guidance

Danaher shares are trading higher after the company reported better-than-expected Q3 adjusted EPS and sales.

For Q4 2024, Danaher Anticipates That Adjusted Core Revenue Will Decline Low-single Digits YoY, For FY2024, The Company Continues To Expect That Adjusted Core Revenue Will Be Down Low-Single Digits YoY

Danaher Q3 2024 Adj. EPS $1.71 Beats $1.57 Estimate, Sales $5.798B Beat $5.587B Estimate

Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) is set to give its latest quarterly earnings report on Tuesday, 2024-10-22. Here's what investors need to know before the announcement.
Analysts estimate that Danaher will report an earnings per share (EPS) of $1.57. 
Anticipation surrounds Danaher's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Performance in Previous Earnings</h3>
During the last quarter, the company reported an EPS beat by $0.15, leading to a 0.6% increase in the share price on the subsequent day.
Here's a look at Danaher's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.57</td>
<td>1.71</td>
<td>1.89</td>
<td>1.76</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.72</td>
<td>1.92</td>
<td>2.09</td>
<td>2.02</td>
</tr>
<tr>
<td>Price Change %</td>
<td>1.0%</td>
<td>-1.0%</td>
<td>-2.0%</td>
<td>-2.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1729522903_0.png" alt="eps graph" />
<h3>Danaher Share Price Analysis</h3>
Shares of Danaher were trading at $274.38 as of October 18. Over the last 52-week period, shares are up 38.08%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. 
<h3>Insights Shared by Analysts on Danaher</h3>
Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Danaher.
Danaher has received a total of 12 ratings from analysts, with the consensus rating as Outperform. With an average one-year price target of $283.42, the consensus suggests a potential 3.29% upside.
<h3>Analyzing Analyst Ratings Among Peers</h3>
The analysis below examines the analyst ratings and average 1-year price targets of Thermo Fisher Scientific, IQVIA Hldgs and Agilent Technologies, three significant industry players, providing valuable insights into their relative performance expectations and market positioning.
<ul>
<li>The consensus among analysts is an Outperform trajectory for Thermo Fisher Scientific, with an average 1-year price target of $665.4, indicating a potential 142.51% upside.</li>
<li>Analysts currently favor an Outperform trajectory for IQVIA Hldgs, with an average 1-year price target of $273.14, suggesting a potential 0.45% downside.</li>
<li>Agilent Technologies received a Neutral consensus from analysts, with an average 1-year price target of $148.78, implying a potential 45.78% downside.</li>
</ul>
<h3>Peer Analysis Summary</h3>
Within the peer analysis summary, vital metrics for Thermo Fisher Scientific, IQVIA Hldgs and Agilent Technologies are presented, shedding light on their respective standings within the industry and offering valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Danaher</td>
<td>Outperform</td>
<td>-2.86%</td>
<td>$3.43B</td>
<td>1.76%</td>
</tr>
<tr>
<td>Thermo Fisher Scientific</td>
<td>Outperform</td>
<td>-1.37%</td>
<td>$4.35B</td>
<td>3.33%</td>
</tr>
<tr>
<td>IQVIA Hldgs</td>
<td>Outperform</td>
<td>2.31%</td>
<td>$1.33B</td>
<td>5.56%</td>
</tr>
<tr>
<td>Agilent Technologies</td>
<td>Neutral</td>
<td>-5.62%</td>
<td>$855M</td>
<td>4.65%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Danaher ranks at the top for Gross Profit and Return on Equity among its peers. It is in the middle for Revenue Growth.
<h3>All You Need to Know About Danaher</h3>
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in the life science and diagnostic industries after the late 2023 divesititure of its environmental and applied solutions group, Veralto.
<h3>Danaher: A Financial Overview</h3>
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Negative Revenue Trend: Examining Danaher's financials over 3 months reveals challenges. As of 30 June, 2024, the company experienced a decline of approximately -2.86% in revenue growth, reflecting a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Danaher's net margin excels beyond industry benchmarks, reaching 15.79%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 1.76%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Danaher's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.12% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Danaher's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.34.
<a href="https://www.benzinga.com/quote/DHR/earnings">To track all earnings releases for Danaher visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Preview: Danaher

Another billionaire investor is rooting for Republican presidential candidate Donald Trump&#8217;s victory in the Nov. 5 election and has accordingly positioned his portfolio. The call comes on the heels of former hedge fund manager Stanley Druckenmiller&#8216;s<a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41375637/market-very-convinced-of-a-trump-win-says-stanley-druckenmiller-why-billionaire-inv"> similar prediction.</a>
What&#8217;s In Store In Political Arena: &#8220;We believe that the likelihood of a Republican victory in the White House has increased, which would have a positive impact on certain sectors and the market overall,&#8221; said hedge fund Third Point founder and CEO Daniel Loeb said in the firm&#8217;s third-quarter investor letter. 
The hedge fund manager said the &#8220;America First&#8221; tariffs will increase domestic manufacturing, infrastructure spending, and prices of certain materials and commodities. He also said a potential reduction in regulation in the activist antitrust stance of the Biden-Harris administration would unleash productivity and a wave of corporate activity.
&#8220;Accordingly, we have increased certain positions that could benefit from such a scenario via both stock and option purchases and continue to shift our portfolio away from companies that will not,&#8221; the hedge fund manager said. A study of Senate races will likely see Republicans establishing a majority, thus precluding a &#8220;Blue Sweep&#8221; if Kamala Harris wins the race to the White House, according to the hedge-fund manager.
He warned of a &#8220;Blue sweep&#8221; theoretically ushering in crushing taxes, stifling regulations, and a headwind to growth.
See Also:<a href="https://www.benzinga.com/money/cyclical-stocks"> What Are Cyclical Stocks</a>
Economic Outlook: Loeb reassured investors regarding the economy. &#8220;In the economy, we see no evidence of recession, slowing inflation, and a real interest rate that still needs to come down,&#8221; he said.
The hedge fund manager also sees healthy consumer spending, and active levels of individual investing, providing a liquidity backdrop to sustain market levels. The setup is good for event-driven investing, he said, adding that &#8220;the potential for risk arbitrage transactions and corporate activity could usher in a golden age for the strategy.&#8221;
Third Point&#8217;s Q3 Winners &amp; Losers: Third Point Offshore Fund generated a return of 3.9%, taking the annualized net returns to 13.1%. The third-quarter returns of the fund, however, paled before the S&amp;P 500&#8217;s 5.9% gain and the MSCI World Index&#8217;s 6.5% rise.
Loeb noted that the global market gains continued in the third quarter but the rally broadened out in the quarter, with the Magnificent 7 trailing the broader market for the first time since the fourth quarter of 2022. Rate-sensitive stocks and cyclicals outperformed as the market looked ahead to the easing cycle, he added.
The top gainers and decliners of the fund are as follows:
Gainers
<ul>
<li>Privately-held R2 Semiconductor</li>
<li>PG&amp;E Corporation&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PCG#NYSE">PCG</a>) Pacific Gas and Electric Company&nbsp;subsidiary</li>
<li>Utility Vistra Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VST#NYSE">VST</a>)</li>
<li>KB Home (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KBH#NYSE">KBH</a>)</li>
<li>Lifesciences and diagnostics company Danaher Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>)</li>
</ul>
Losers:
<ul>
<li>Bath &amp; Body Works, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBWI#NYSE">BBWI</a>)</li>
<li>Amazon.com, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>)</li>
<li>Advance Auto Parts, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AAP#NYSE">AAP</a>)</li>
<li>Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>)</li>
<li>Microsoft Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>)</li>
</ul>
Loeb also said his fund initiated a position in Danish freight forwarder DSV. &#8220;We believe DSV can earn more than 100 DKK per share in 2027 and see significant upside for one of Europe's best companies,&#8221; he said.
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>), an exchange-traded fund that tracks the performance of the S&amp;P 500 Index, traded up 0.25% to $583.78&nbsp;in premarket trading on Friday, according to<a href="https://benzinga.grsm.io/register174"> Benzinga Pro data.</a>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/10/41374232/amid-nvidias-stratospheric-rally-billionaire-investor-druckenmiller-regrets-cashing-out-of-ai-st">Amid Nvidia&#8217;s Stratospheric Rally, Billionaire Investor Druckenmiller Regrets Cashing Out Of AI Stalwart&#8217;s Stock: &#8216;I&#8217;m Licking My Wounds From A Bad Sale&#8217;</a></li>
</ul>
Image via Flickr

Economics

AMZN

BBWI

GOOG

GOOGL

MSFT

Hedge Fund Billionaire Daniel Loeb Bets On Trump Win, Singles Out This Recent Buy As Having 'Significant Upside Potential'

Deep-pocketed investors have adopted a bearish approach towards Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in DHR usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 24 extraordinary options activities for Danaher. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 41% leaning bullish and 50% bearish. Among these notable options, 22 are puts, totaling $1,018,942, and 2 are calls, amounting to $107,750.
<h3>Expected Price Movements</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $262.5 to $330.0 for Danaher over the last 3 months. 
<h3>Volume &amp; Open Interest Development</h3>
In today's trading context, the average open interest for options of Danaher stands at 817.88, with a total volume reaching 7,139.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Danaher, situated within the strike price corridor from $262.5 to $330.0, throughout the last 30 days.
<h3>Danaher Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1729098958_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>DHR</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$1.55</td>
<td>$1.15</td>
<td>$1.25</td>
<td>$262.50</td>
<td>$87.5K</td>
<td>234</td>
<td>1.0K</td>
</tr>
<tr>
<td>DHR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$6.2</td>
<td>$5.7</td>
<td>$5.7</td>
<td>$270.00</td>
<td>$70.1K</td>
<td>1.7K</td>
<td>684</td>
</tr>
<tr>
<td>DHR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$4.5</td>
<td>$3.8</td>
<td>$4.4</td>
<td>$270.00</td>
<td>$59.8K</td>
<td>1.7K</td>
<td>496</td>
</tr>
<tr>
<td>DHR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$1.4</td>
<td>$0.95</td>
<td>$1.4</td>
<td>$275.00</td>
<td>$56.0K</td>
<td>2.0K</td>
<td>562</td>
</tr>
<tr>
<td>DHR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$16.1</td>
<td>$15.7</td>
<td>$16.1</td>
<td>$280.00</td>
<td>$53.0K</td>
<td>429</td>
<td>0</td>
</tr>
</tbody>
</table>

<h3>About Danaher</h3>
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in the life science and diagnostic industries after the late 2023 divesititure of its environmental and applied solutions group, Veralto.
In light of the recent options history for Danaher, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Present Market Standing of Danaher</h3>
<ul>
<li>With a trading volume of 908,531, the price of DHR is down by -2.15%, reaching $266.83.</li>
<li>Current RSI values indicate that the stock is is currently neutral between overbought and oversold.</li>
<li>Next earnings report is scheduled for 6 days from now.</li>
</ul>
<h3>What Analysts Are Saying About Danaher</h3>
Over the past month, 2 industry analysts have shared their insights on this stock, proposing an average target price of $296.5.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Reflecting concerns, an analyst from Stephens &amp; Co. lowers its rating to Overweight with a new price target of $315. 
&#x2A; An analyst from Evercore ISI Group has decided to maintain their Outperform rating on Danaher, which currently sits at a price target of $278. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Danaher, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

This Is What Whales Are Betting On Danaher

Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) has outperformed the market over the past 10 years by 6.5% on an annualized basis producing an average annual return of 18.16%. Currently, Danaher has a market capitalization of $196.21 billion. 
Buying $100 In DHR: If an investor had bought $100 of DHR stock 10 years ago, it would be worth $541.15 today based on a price of $271.68 for DHR at the time of writing.
<h3>Danaher's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1728936018_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Danaher Stock In The Last 10 Years

Danaher's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) short percent of float has risen 5.83% since its last report. The company recently reported that it has 7.01 million shares sold short, which is 1.09% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.86 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Danaher Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1728063924_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Danaher has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Danaher's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Danaher's peer group average for short interest as a percentage of float is 5.53%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Looking Into Danaher's Recent Short Interest

Evercore ISI Group analyst Vijay Kumar maintains Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) with a Outperform and raises the price target from $275 to $278.

Evercore ISI Group Maintains Outperform on Danaher, Raises Price Target to $278

Shares of Danaher Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) <a href="https://www.benzinga.com/quote/DHR">tanked in early trading on Tuesday</a>.
Stifel <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5def9513bffdfc0001938cfc/jacob-johnson">analyst Jacob Johnson</a> says the company is poised for a gradual recovery in 2025. It could generate high-single-digit growth in the longer term, he predicts.
The Danaher Thesis: Johnson initiated coverage of Danaher with an Overweight rating and price target of $315.
Danaher completed a spinoff of its Environmental &amp; Applied Solutions business in 2023. The company then emerged as a "pure-play LS tools company with operating companies in the Biotechnology, Life Sciences, and Diagnostics end-markets," Johnson added.
Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
The EAS spinoff eliminated much of Danaher's industrial exposure. As a life sciences company, it remains focused on "higher growth, recurring revenue, and margins that warrant a higher multiple," the analyst stated.
"Like the broader space, DHR has faced headwinds over the last 12 to 18 months from bioprocessing destocking, the funding environment, China, and the roll-off from COVID," he wrote, while expressing optimism around "a gradual recovery in 2025 (with a good year in bioprocessing)."
DHR Price Action: Danaher shares declined by 1.05% to $275.07 at the time of publication on Tuesday.
Read More: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/07/40036664/jim-cramer-says-no-to-this-health-care-stock-recommends-holding-on-to-constellation-ener">Jim Cramer Says No To This Health Care Stock, Recommends Holding On To Constellation Energy: &#8216;It&#8217;s Up A Huge Amount&#8217;</a></li>
</ul>
Image: Shutterstock

Initiation

Danaher Is Poised For 'A Good Year In Bioprocessing': Analyst

Stephens &amp; Co. analyst Jacob Johnson initiates coverage on Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) with a Overweight rating and announces Price Target of $315.

Stephens & Co. Initiates Coverage On Danaher with Overweight Rating, Announces Price Target of $315

Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) has outperformed the market over the past 10 years by 7.27% on an annualized basis producing an average annual return of 18.66%. Currently, Danaher has a market capitalization of $199.90 billion. 
Buying $1000 In DHR: If an investor had bought $1000 of DHR stock 10 years ago, it would be worth $5,524.26 today based on a price of $276.79 for DHR at the time of writing.
<h3>Danaher's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727454629_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In Danaher 10 Years Ago Would Be Worth This Much Today

Whales with a lot of money to spend have taken a noticeably bearish stance on Danaher.
Looking at options history for Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) we detected 38 trades.
If we consider the specifics of each trade, it is accurate to state that 28% of the investors opened trades with bullish expectations and 57% with bearish.
From the overall spotted trades, 12 are puts, for a total amount of $675,331 and 26, calls, for a total amount of $1,751,865.
<h3>Expected Price Movements</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $100.0 to $340.0 for Danaher during the past quarter. 
<h3>Volume &amp; Open Interest Trends</h3>
In terms of liquidity and interest, the mean open interest for Danaher options trades today is 552.21 with a total volume of 12,900.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Danaher's big money trades within a strike price range of $100.0 to $340.0 over the last 30 days.
<h3>Danaher Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727381814_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>DHR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$10.5</td>
<td>$10.4</td>
<td>$10.4</td>
<td>$280.00</td>
<td>$158.0K</td>
<td>1.6K</td>
<td style="text-align: right;">579</td>
</tr>
<tr>
<td>DHR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>12/20/24</td>
<td>$10.4</td>
<td>$10.1</td>
<td>$10.4</td>
<td>$280.00</td>
<td>$144.5K</td>
<td>1.6K</td>
<td style="text-align: right;">792</td>
</tr>
<tr>
<td>DHR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$10.6</td>
<td>$9.2</td>
<td>$10.4</td>
<td>$280.00</td>
<td>$132.0K</td>
<td>1.6K</td>
<td style="text-align: right;">993</td>
</tr>
<tr>
<td>DHR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$19.3</td>
<td>$18.6</td>
<td>$19.3</td>
<td>$260.00</td>
<td>$115.8K</td>
<td>617</td>
<td style="text-align: right;">60</td>
</tr>
<tr>
<td>DHR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$19.0</td>
<td>$18.6</td>
<td>$19.0</td>
<td>$260.00</td>
<td>$114.0K</td>
<td>617</td>
<td style="text-align: right;">120</td>
</tr>
</tbody>
</table>

<h3>About Danaher</h3>
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in the life science and diagnostic industries after the late 2023 divesititure of its environmental and applied solutions group, Veralto.
<h3>Current Position of Danaher</h3>
<ul>
<li>With a trading volume of 2,617,178, the price of DHR is up by 3.38%, reaching $276.93.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 26 days from now.</li>
</ul>
<h3>What The Experts Say On Danaher</h3>
1 market experts have recently issued ratings for this stock, with a consensus target price of $300.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Reflecting concerns, an analyst from RBC Capital lowers its rating to Outperform with a new price target of $300.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Danaher with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Spotlight on Danaher: Analyzing the Surge in Options Activity

Investors with a lot of money to spend have taken a bullish stance on Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with DHR, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 9 uncommon options trades for Danaher.
This isn't normal.
The overall sentiment of these big-money traders is split between 44% bullish and 44%, bearish.
Out of all of the special options we uncovered, 5 are puts, for a total amount of $239,254, and 4 are calls, for a total amount of $843,215.
<h3>Expected Price Movements</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $270.0 to $290.0 for Danaher during the past quarter. 
<h3>Insights into Volume &amp; Open Interest</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Danaher's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Danaher's significant trades, within a strike price range of $270.0 to $290.0, over the past month.
<h3>Danaher Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727121683_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>DHR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$18.3</td>
<td>$17.9</td>
<td>$18.3</td>
<td>$270.00</td>
<td>$549.0K</td>
<td>1.3K</td>
<td style="text-align: right;">305</td>
</tr>
<tr>
<td>DHR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$5.1</td>
<td>$4.9</td>
<td>$4.9</td>
<td>$275.00</td>
<td>$169.5K</td>
<td>0</td>
<td style="text-align: right;">658</td>
</tr>
<tr>
<td>DHR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$5.0</td>
<td>$4.9</td>
<td>$5.0</td>
<td>$275.00</td>
<td>$67.5K</td>
<td>0</td>
<td style="text-align: right;">275</td>
</tr>
<tr>
<td>DHR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$5.0</td>
<td>$4.9</td>
<td>$5.0</td>
<td>$275.00</td>
<td>$57.1K</td>
<td>0</td>
<td style="text-align: right;">123</td>
</tr>
<tr>
<td>DHR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$19.3</td>
<td>$18.7</td>
<td>$19.09</td>
<td>$290.00</td>
<td>$49.7K</td>
<td>89</td>
<td style="text-align: right;">26</td>
</tr>
</tbody>
</table>

<h3>About Danaher</h3>
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in the life science and diagnostic industries after the late 2023 divesititure of its environmental and applied solutions group, Veralto.
After a thorough review of the options trading surrounding Danaher, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Where Is Danaher Standing Right Now?</h3>
<ul>
<li>With a volume of 1,107,680, the price of DHR is up 0.37% at $273.65. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 29 days.</li>
</ul>
<h3>What Analysts Are Saying About Danaher</h3>
Over the past month, 2 industry analysts have shared their insights on this stock, proposing an average target price of $290.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Wells Fargo has revised its rating downward to Equal-Weight, adjusting the price target to $280. 
&#x2A; An analyst from RBC Capital downgraded its action to Outperform with a price target of $300. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Danaher options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Danaher Unusual Options Activity

Financial giants have made a conspicuous bearish move on Danaher. Our analysis of options history for Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) revealed 13 unusual trades.
Delving into the details, we found 38% of traders were bullish, while 53% showed bearish tendencies. Out of all the trades we spotted, 6 were puts, with a value of $246,114, and 7 were calls, valued at $330,370.
<h3>Projected Price Targets</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $95.0 to $290.0 for Danaher over the recent three months. 
<h3>Volume &amp; Open Interest Development</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Danaher's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Danaher's significant trades, within a strike price range of $95.0 to $290.0, over the past month.
<h3>Danaher 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1725898546_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th style="text-align: right;">Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>DHR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$182.8</td>
<td>$179.2</td>
<td>$179.2</td>
<td>$95.00</td>
<td>$89.6K</td>
<td style="text-align: right;">580</td>
<td style="text-align: right;">11</td>
</tr>
<tr>
<td>DHR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$139.9</td>
<td>$137.0</td>
<td>$138.5</td>
<td>$135.00</td>
<td>$55.4K</td>
<td style="text-align: right;">144</td>
<td style="text-align: right;">10</td>
</tr>
<tr>
<td>DHR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$17.9</td>
<td>$17.5</td>
<td>$17.58</td>
<td>$280.00</td>
<td>$52.7K</td>
<td style="text-align: right;">769</td>
<td style="text-align: right;">85</td>
</tr>
<tr>
<td>DHR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$18.3</td>
<td>$17.8</td>
<td>$18.14</td>
<td>$280.00</td>
<td>$49.0K</td>
<td style="text-align: right;">769</td>
<td style="text-align: right;">55</td>
</tr>
<tr>
<td>DHR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$17.8</td>
<td>$17.5</td>
<td>$17.51</td>
<td>$280.00</td>
<td>$43.7K</td>
<td style="text-align: right;">769</td>
<td style="text-align: right;">110</td>
</tr>
</tbody>
</table>

<h3>About Danaher</h3>
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in the life science and diagnostic industries after the late 2023 divesititure of its environmental and applied solutions group, Veralto.
Following our analysis of the options activities associated with Danaher, we pivot to a closer look at the company's own performance.
<h3>Danaher's Current Market Status</h3>
<ul>
<li>With a trading volume of 661,435, the price of DHR is up by 1.69%, reaching $270.69.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 43 days from now.</li>
</ul>
<h3>Professional Analyst Ratings for Danaher</h3>
2 market experts have recently issued ratings for this stock, with a consensus target price of $290.0.
<ul>
<li>An analyst from Wells Fargo has revised its rating downward to Equal-Weight, adjusting the price target to $280. </li>
<li>Reflecting concerns, an analyst from RBC Capital lowers its rating to Outperform with a new price target of $300.</li>
</ul>
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Danaher, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Unpacking the Latest Options Trading Trends in Danaher

Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) has outperformed the market over the past 10 years by 7.37% on an annualized basis producing an average annual return of 17.83%. Currently, Danaher has a market capitalization of $191.18 billion. 
Buying $1000 In DHR: If an investor had bought $1000 of DHR stock 10 years ago, it would be worth $5,180.69 today based on a price of $264.71 for DHR at the time of writing.
<h3>Danaher's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1725643820_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Dividend Champion, Contender, And Challenger Highlights: Week Of October 20

Earnings week ahead: TSLA, GE, GM, KO, PM, LUV, AAL, VZ, T and more

Danaher Q3 2024 Earnings Preview

Notable companies reporting before tomorrow's open, with earnings consensus, include GE Aerospace (GE), consensus $1.14… Danaher (DHR), consensus $...

Notable companies reporting before tomorrow's open

Here's the major earnings before the open tomorrow

Danaher Non-GAAP EPS of $1.71 beats by $0.14, revenue of $5.8B beats by $210M

The company said, "For full year 2024, the Company continues to expect that non-GAAP core revenue will be down low-single digits year-over-year." P...

Danaher backs FY24 revenue view down low-single digits

Reports Q3 revenue $5.8B, consensus $5.59B. Rainer Blair, president and CEO, stated, "Our team delivered strong third quarter results, including be...

Danaher reports Q3 adjusted EPS $1.71, consensus $1.57

The company said, "For the fourth quarter 2024, the Company anticipates that non-GAAP core revenue will decline low-single digits year-over-year." ...

Danaher sees Q4 revenue down low-single digits

Danaher perks up as broad-based performance drives Q3 beat

AGNC

APOG

CARR

CMCSA

CSCO

CSWI

DENN

ERIE

ESRT

FAST

FBNC

GAIN

GATX

HBCP

HFBL

INGR

JOUT

LAND

LECO

LKFN

LRCX

ORCL

OTIS

PCAR

QNTO

SPFI

TMUS

TSLA

TXNM

VALE

Press Releases

Danaher Launches Beacon Research Collaboration with Stanford University Aiming to Build Next Generation of Smart Microscopes for Cancer Drug Screening

Danaher Releases 2024 Sustainability Report

Danaher Announces Two New Centers of Innovation in Diagnostics to Transform Precision Medicine Development

Beckman Coulter's DxI 9000 Immunoassay Analyzer Honored at Premier, Inc.'s Annual Supplier Innovation Celebration

Danaher to Webcast Diagnostics Investor & Analyst Meeting in Washington, D.C.

Danaher Confirms Third Quarter and Full Year 2024 Guidance

Dividends

Danaher Announces Quarterly Dividend

Beckman Coulter and Scopio Labs Add World's First Digital Bone Marrow Imaging and Analysis to Long-Term Partnership

Danaher Schedules Third Quarter 2024 Earnings Conference Call

Danaher Reports Third Quarter 2024 Results

Agilent Technologies

AbCellera Biologics

Avantor

Azenta

Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories

BioLife Solns

Bruker

Charles River Laboratories International, Inc. Common Stock

Charles River

Evotec SE - American Depositary Shares each representing 1/2 of one ordinary share

Comments

Danaher

Danaher (DHR) Options

Danaher (NYSE:DHR) Stock, Chaîne d'Options

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL